International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis.
Álvaro Díaz-GonzálezMarco Sanduzzi-ZamparelliLeonardo Gomes da FonsecaGiovan G Di CostanzoRogerio AlvesMassimo IavaroneCassia LealRodolfo SaccoAna M MatillaManuel Hernández GuerraGabriel Aballay SoterasMarcus-Alexander WörnsMatthias PinterMaria VarelaMorten LadekarlAline Lopes ChagasBeatriz MínguezJuan I ArenasAlessandro GranitoYolanda Sánchez-TorrijosÁngela RojasCarlos Rodríguez de LopeMario R Alvares-da-SilvaSonia PascualLorenza RimassaJosé L LledóCarlos HuertasBruno SangroEdoardo Giovanni GianniniManuel DelgadoMercedes VergaraChristie PerellóAlberto LueMargarita SalaAdolfo GallegoSusanna CollTania HernáezFederico PiñeroGustavo Henrique Santos PereiraAlex FrançaJuan MarínMargarita AndersVivianne MelloMar LozanoJean Charles NaultJosemaría MenéndezIgnacio García JuárezJordi BruixMaria ReigPublished in: Liver international : official journal of the International Association for the Study of the Liver (2020)
The outcomes observed in this cohort seem comparable to those in the non-dialysis population. Thus, to the best of our knowledge, this is the largest and most informative dataset regarding systemic treatment outcomes in HCC patients undergoing dialysis.